DSG3 and acquired polycythemia vera: The B cell-depleting monoclonal anti-CD20 antibody rituximab leads to a marked decrease of Dsg3 auto-ab-titers paralleled by a fast clinical remission in the majority of PV patients (16–18), underlining the crucial role of continuous auto-ab production in PV by Dsg3-specific B cells, plasmablasts, and plasma cells.